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Osteochondral Allografting – The First 100 Years
Wiliam Bugbee, MD and Simon Gortz, MD, San Diego, CA, USA
Transplantation of homologous joint tissue was initially reported on 
in the European literature at the turn of the 20th century(1). German 
surgeons Erich Lexer and Hermann Küttner are generally considered 
the pioneers of employing allogeneic tissue in joint resurfacing. 
Osteochondral allografting seemingly became forgotten during the 
struggles of the world wars but underwent a renaissance in the latter 
part of the century largely due to its clinical success at institutionalized 
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of small fragment fresh osteochondral allografting has since been 
well documented in the orthopaedic literature and over the past 
quarter century has established itself as a viable option for biologic 
reconstruction in major joints.
Allografts can address a broad spectrum of articular and 
osteoarticular pathology, particularly in conditions that include both 
an osseous and a chondral component, by restoring the anatomy 
of the native joint both macroscopically and microscopically with a 
solid orthotopic replacement. Transplanting structurally complete 
osteochondral units with an intact tidemark reliably relegates 
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of inducing donor site morbidity. The fundamental paradigm of 
fresh osteochondral allografting is that mature orthotopic hyaline 
cartilage, with viable chondrocytes that survive hypothermic storage 
and transplantation, maintains its metabolic activity and sustains 
the extracellular matrix in a functional mechanical state after 
transplantation(4). Employing fresh tissue, it has been demonstrated 
- primarily through retrieval studies - that viable chondrocytes are 
present and mechanical properties of the matrix are maintained 
many years after transplantation(5-7). 
These human allograft retrieval studies have also shown that 
patients immunologically tolerate the transplant(8), with little or 
no histological evidence of immune-mediated pathology or frank 
transplant rejection(9, 10). Thus, no immunomodulation is currently 
employed in clinical practice. The exposure to residual antigenic 
bone soluble proteins and marrow elements can elicit a variable 
immune response in the host, not unlike that seen in allogenous bone 
grafting(11). The clinical relevance of the variable immunological 
phenomena encountered in osteochondral allografting is yet 
undetermined but the implanted osseous portion of the graft is 
generally limited to a few millimeters, depending on how much 
bone is required to restore injured or absent subchondral tissue. 
This is done to minimize antigenic load and to facilitate osseous 
consolidation via creeping substitution by the host bone.
Depending on the site and characteristics of the lesion, either 
shell grafts or dowel plugs can be employed to recreate native 
anatomy(12). Shell grafting is the traditional surgical technique for 
osteochondral allografting that involves free-hand fashioning of an 
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The shell technique remains the method of choice for complex, very 
large and hard to access locations, as well as lesions of the tibia and 
patella. Over the last decade, dowel plugs have gained popularity, 
especially for femoral lesions. These are circular plugs that are 
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while seating the dowels has been shown to expose the articular 
cartilage to injury during implantation and to trigger apoptotic 
cascades that lead to chondrocyte death(13). Precise surgical 
technique to maintain cartilage health and achieve joint congruence 
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the most important factors for successful clinical outcomes. 
In the knee, focal femoral lesions have traditionally shown the 
best results(14, 15), although lesions on the tibial side(16) and in 
the patellofemoral joint(17, 18) have also shown to be amenable 
to allografting. Indications include osteochondritis dissecans(19, 
20), degenerative or traumatic cartilage lesions(21), post-traumatic 
osteoarthrosis(22) and osteonecrosis(23). Long-term clinical follow-
up studies generally have shown success rates in excess of 75%. 
Osteochondral allografts have also been successfully employed in 
other joints. Allografting has been proven successful in the ankle, 
where indications include osteochondral lesions of the talus, 
osteonecrosis and osteoarthritis(24). In fact, bipolar allografting of 
the tibiotalar joint constitutes the use that most closely resembles 
a true biologic arthroplasty solution. In the hip and shoulder joints 
allografting has been successful in isolated cases, although further 
applications are currently still evolving.
These favorable clinical results were largely achieved by transplanting 
fresh osteochondral tissue within a week of donor death under an 
exceptional release protocol. Fresh osteochondral allografts became 
widely available in the United States through commercial tissue 
banking and distribution only at the turn of the millennium. In a 
deviation from prior protocol, tissue banks now routinely hold grafts 
for 7-28 days to allow completion of microbiologic and serologic 
testing prior to release. Balancing the essential considerations 
of graft safety and optimization of chondrocyte health remains 
controversial, and maximizing both factors has increasingly been the 
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Many recent investigations have focused on increasing the storage 
interval of fresh human osteochondral allograft tissue. In comparing 
the effects of different storage media on human osteochondral 
allograft tissue when stored hypothermically, a standard culture 
media containing nutritive factors proved superior to elemental 
lactated Ringer’s solution(25). This nutritive culture media is the 
current standard of practice in all U.S. tissue banks’ graft processing 
protocols. 
The effects of prolonged storage on allograft tissue quality after 
cold storage have also been investigated at length, examining the 
articular cartilage of fresh human osteochondral allografts after 
cold storage in culture media(26). All of these studies showed an 
inverse relation between time to implant and chondrocyte health. 
The exact mechanism underlying this phenomenon is still a topic of 
speculation, but likely encompasses elements of both necrosis and 
apoptosis, as gene array analysis found up-regulation of several 
pivotal contributors including caspases, the effector enzymes of the 
apoptotic cascade, with prolonged storage of fresh osteochondral 
allografts(27). 
From retrieval studies, it seems apparent that viable chondrocytes 
are essential for maintaining the integrity of the surrounding matrix in 
articular cartilage and thus tissue homeostasis. Several other studies 
have suggested that the relative resilience of the matrix during the 
short study intervals merely represents a lag effect before inevitable 
degradation, which would become evident in longer follow-up(28). 
However, the threshold of chondrocyte viability needed to ensure 
clinical success in osteochondral allografting remains unknown. 
 Attempts at cryopreservation and freezing to prolong the window 
of storage have shown that they are, at the present time, not 
adequate methods to preserve chondrocyte viability in surgical 
grafts(29). While this has been effectively accomplished in isolated 
chondrocytes in suspension, the cell viability in articular cartilage 
frozen in situ has been shown to be highly variable and generally 
inadequate after such cryoinjury in different studies. Furthermore, 
retrieval of osteoarticular allografts indicates that the articular 
matrix in frozen allografts deteriorates over time, presumably 
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not supported the use of cryopreserved or frozen tissue for small 
osteochondral allografts in the setting of reconstruction of chondral 
and osteochondral defects.
 Osteochondral allografts have emerged to play an increasingly vital 
role in the clinical algorithm of cartilage restoration, to the point where 
supply of suitable graft tissue, rather than restrictions in indications, 
has become the limiting factor in their clinical application. In order 
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of the tissue must be maximized while ensuring its timely availability 
to doctors and, ultimately, patients. To accomplish this goal, more 
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As with other cartilage-restorative methods, the indications for 
the use of fresh osteochondral allografts are still being expanded 
with respect to the use of allografts in the primary treatment of 
focal femoral condyle lesions, the use of allografts in joints with 
advanced burden of disease as well as the application in other 
joints. In addition, allogeneic tissue holds promise as an alternative 
yet abundant cell or mature matrix source for future generations of 
cartilage repair procedures.
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